Edgewise Therapeutics Inc. Common Stock vs Venture Global Inc. Class A common stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.32 (market cap $3.94B), while Venture Global Inc. Class A common stock trades at $13.22 (market cap $34.60B). The key difference: Venture Global Inc. Class A common stock is far larger — about 8.8× Edgewise Therapeutics Inc. Common Stock's market cap, and Venture Global Inc. Class A common stock pays a 1.16% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Venture Global Inc. Class A common stock for 1 Days on average.
| EWTX | VG | |
|---|---|---|
Market Cap | $3.94B | $34.60B |
Volume | 810,104 | 11,731,839 |
Sector | Health | Energy |
52-Week High | $48.35 | $17.53 |
52-Week Low | $14.89 | $5.92 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $3.48B | $73.99B |
Dividend Yield | — | 1.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VG trades at $13.84, up 5.41% today, with a bearish technical signal but strong fundamentals including a 21.24% net income margin and 48.13% ROE. Recent earnings have consistently beaten estimates, and the company is expanding LNG capacity to 85 MTPA by 2029, supported by long-term supply deals like the 20-year agreement with ConocoPhillips announced on October 1, 2026.
The stock offers value with a P/E of 10.52 and consensus price target of $16.13, but faces risks from high short interest and negative net cash flow in 2025. Analyst sentiment is bullish with 58% buy ratings, though technical indicators suggest near-term caution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →